Eton Pharmaceuticals (ETON) Aktienübersicht
Eton Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von Behandlungen für seltene Krankheiten konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
ETON Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Eton Pharmaceuticals, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$36.61 |
| 52-Wochen-Hoch | US$38.62 |
| 52-Wochen-Tief | US$13.76 |
| Beta | 0.86 |
| 1 Monat Veränderung | 18.29% |
| 3 Monate Veränderung | 38.88% |
| 1 Jahr Veränderung | 152.66% |
| 3 Jahre Veränderung | 1,132.66% |
| 5 Jahre Veränderung | 572.98% |
| Veränderung seit IPO | 485.76% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.
Narrativ-Update • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.Narrativ-Update • Jun 01
ETON: Higher 2026 Guidance And New Rare Disease Assets Will Drive Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $57 from $35, citing higher fiscal 2026 revenue guidance, stronger profitability assumptions, and confidence in the company’s growth strategy as key reasons for the revised valuation. Analyst Commentary Recent research updates show a clear cluster of bullish analysts raising their fair value assumptions on Eton Pharmaceuticals, with several target bumps tied directly to the company’s latest revenue outlook and portfolio moves.Recent updates
Narrativ-Update • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.Narrativ-Update • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.Narrativ-Update • Jun 01
ETON: Higher 2026 Guidance And New Rare Disease Assets Will Drive Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $57 from $35, citing higher fiscal 2026 revenue guidance, stronger profitability assumptions, and confidence in the company’s growth strategy as key reasons for the revised valuation. Analyst Commentary Recent research updates show a clear cluster of bullish analysts raising their fair value assumptions on Eton Pharmaceuticals, with several target bumps tied directly to the company’s latest revenue outlook and portfolio moves.Narrativ-Update • May 03
ETON: Single New Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Analysts have lifted their price targets on Eton Pharmaceuticals by up to $15, citing updated assumptions for revenue growth, profit margins, and future P/E that reflect the recent Hemangeol acquisition and its potential contribution to the business. Analyst Commentary Recent research updates around Eton Pharmaceuticals focus heavily on the Hemangeol acquisition and how it might reshape the company’s growth mix, earnings profile, and valuation assumptions.Narrativ-Update • Apr 18
ETON: Hemangioma Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Narrative Update on Eton Pharmaceuticals Analysts have raised their price targets on Eton Pharmaceuticals by up to $15, citing the Hemangeol acquisition, its existing FDA approval for infantile hemangioma, and the view that the deal could be accretive with commercialization planned to begin in May. Analyst Commentary Bullish analysts are generally positive on Eton Pharmaceuticals following the acquisition of the U.S. rights to Hemangeol, and several have raised their price targets in response.Narrativ-Update • Apr 04
ETON: Hemangioma Franchise Expansion Will Reshape Earnings Profile Through 2026
Analysts have raised the consolidated price target for Eton Pharmaceuticals from $30.00 to about $39.33, citing recent target increases from multiple firms and updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Eton Pharmaceuticals focuses heavily on the updated price targets, the Hemangeol acquisition, and how realistic current modeling assumptions appear against execution risks.
Narrativ-Update • Mar 21
ETON: Upcoming Product Launches And New Guidance Will Reshape Earnings Profile
Analysts have raised the Eton Pharmaceuticals price target from $26 to $31, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that reflect their latest views on the company following recent research updates. Analyst Commentary Recent research updates highlight a mix of optimism about Eton Pharmaceuticals' growth opportunities and caution around how quickly those opportunities might translate into earnings and justify higher valuation multiples.Seeking Alpha • Jan 23
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth
Summary Eton offers a diversified, acquisition-driven portfolio in ultra-rare pediatric endocrinology and metabolic diseases, targeting significant peak sales potential. My DCF-based Fair Value is $28.1, representing 85% upside; optimistic scenarios suggest up to $40 per share, while downside risk is mitigated by product diversification. Revenue growth, free cash flow positivity, and declining SG&A margins support a Buy-to-Strong Buy stance at $15.17, despite high uncertainty from US drug pricing. My strategy favors incremental share accumulation, with position sizing responsive to technical signals, product launches, and evolving Fair Value estimates. Read the full article on Seeking AlphaAnalyseartikel • Nov 14
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Share Price Matching Investor Opinion
With a price-to-sales (or "P/S") ratio of 6.4x Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) may be sending very bearish...Analyseartikel • Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 17
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 25% after a relatively good period...Neues Narrativ • May 16
Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.Analyseartikel • May 16
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
It's been a pretty great week for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, with its shares surging 14...Analyseartikel • May 02
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders are no doubt pleased to see that the share price has bounced...Analyseartikel • Feb 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Analyseartikel • Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Analyseartikel • Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
The Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) share price has done very well over the last month, posting an excellent...Analyseartikel • Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a really impressive month, gaining 40% after a shaky period...Analyseartikel • Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Market forces rained on the parade of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders today, when the covering...Analyseartikel • Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) earnings announcement last week was disappointing for investors, despite...Analyseartikel • Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 26% after a relatively good period...Analyseartikel • Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyseartikel • Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Sep 13
Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Eton Pharmaceuticals (NASDAQ:ETON) on Tuesday said it had acquired an FDA-approved rare disease product, betaine anhydrous for oral solution. Betaine anhydrous is a chemical that occurs naturally in the body. It helps in the metabolism of a chemical called homocysteine and prevents the buildup of it in the blood. High levels of homocysteine can cause problems with metabolism. The company plans to integrate the product later this year and expects the acquisition to be accretive to 2023 earnings, ETON CEO Sean Brynjelsen said in a statement. ETON stock -4.3% at $2.21 in morning trading.Seeking Alpha • Aug 14
Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Today, we revisit fast evolving biopharma name Eton Pharmaceuticals for the first time since October of last year. Since then, the company has launched several key products and made a key divestiture. What is ahead for this intriguing small cap concern? An investment analysis follows in the paragraphs below. I predict future happiness for Americans, if they can prevent the government from wasting the labors of the people under the pretense of taking care of them. ― Thomas Jefferson It has been almost a year since our last piece on Eton Pharmaceuticals (ETON). The stock shot up soon after that article was posted but has been in pullback mode since. The company posted second quarter results earlier this week. Given that it seems a good to revisit this small cap name. An analysis follows below. Seeking Alpha Company Overview Eton Pharmaceuticals is a commercial-stage biopharmaceutical concern based in Illinois. The company is focused on improving the formula, delivery, and/or safety of approved drugs employing the 505((B))(2) regulatory pathway. The stock currently trades just below three bucks a shares and sports and approximate market capitalization of $75 million. The company is in the early stages of commercialization with several products and has several more than could potentially launch over the next year. May Company Presentation The company breaks down its focus to two main areas. There are royalty products. These are products that are handled by partners with established salesforces for which Eton will get paid milestone payouts as well as royalties on sales. There are Orphan Drug Products which Eton will sell under its own label and have the greatest potential to impact margins and earnings. The company has recently launched two drugs in that category. May Company Presentation The first of which is Carglumic Acid tablets. If the company eventually meets its market share goals, this could be roughly a $15 million product annually. May Company Presentation Alkindi Sprinkle as described above is a much bigger potential opportunity and leadership believes this product could eventually do $100 million in annual sales. The product is 'co-promoted' by Tolmar Pharmaceuticals through their 60 plus sales reps. The company had a Hospital Products division that was gearing up for several commercial launches. However, in late June, Eton sold the rights and interests in Biorphen, Rezipres and Cysteine Hydrochloride products in that division to a subsidiary of Dr. Reddy's Laboratories (RDY). This deal came with a $5 million upfront payment as well as potential additional payments of up to $45 million, based on the achievement of certain event-based and sales-based milestones. This allows Eton to focus solely on its rare disease product portfolio. Second Quarter Results The company posted second quarter numbers on August 11th. Eton had a GAAP loss for the quarter of six cents a share. The consensus was projecting a slight profit for the quarter. Revenues did rise over 140% on a year-over-year basis to $7.4 million, which was slightly below expectations. It should be noted most of revenues was for milestone payments including the $5 million payment netted for the disposal of the assets in its Hospital Product division. Carglumic Acid sales saw 100% sequential growth and Alkindi Sprinkle sales were up 34% from the first quarter of this year, but both are coming off very low numbers as they are at the beginning of commercial launch phase. Zonisade was approved in July and will be marketed by Azurity Pharmaceuticals. During the quarter, Eton made good progress addressing FDA concerns about its marketing application for dehydrated alcohol injection. The company expects to resubmit the application for the product later this year. Approval and launch should occur in 2023. With approval, Eton would one of only 2 suppliers in this approximate $80 million annual market due to the orphan drug exclusivity protections. Management also continue to progress the development of its ZENEO® hydrocortisone autoinjector. A marketing application for this product should be filed with the FDA in 2023. Analyst Commentary & Balance Sheet The company ended the second quarter with $17 million in cash and marketable securities on the balance sheet after posting a net loss of $1.6 million in the second quarter. The company also is entitled to receive an additional $5 million milestone payment upon the launch of the recently approved Zonisade™ product. Approximately five percent of the outstanding float in Eton Pharmaceuticals is currently held short. There also has been no insider activity in the shares so far in 2022.Seeking Alpha • Jul 18
Eton Pharma jumps 20% on FDA approval of seizure therapy
Eton Pharmaceuticals (NASDAQ:ETON), a company focused on rare diseases, added ~20% in the pre-market Monday after the announcement of the FDA approval for Zonisade (zonisamide oral suspension) for the treatment of partial seizures. "ZONISADE™ is the first and only FDA-approved oral liquid formulation of zonisamide, and it offers healthcare providers an important new treatment option for their patients with epilepsy," Chief Executive of Eton (ETON) Richard Blackburn noted. Specifically, the FDA has greenlighted Zonisade oral suspension at 100 mg/5 mL as adjunctive therapy for partial seizures in those aged 16 years and above with epilepsy. In 2021 Feb., Eton (ETON) announced a deal under which Azurity Pharmaceuticals agreed to commercialize Zonisade with no marketing expenses from the company.Aktionärsrenditen
| ETON | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -2.4% | -0.5% | 0.6% |
| 1Y | 152.7% | 45.8% | 19.5% |
Rendite im Vergleich zur Industrie: ETON übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 45.8 erzielte.
Rendite vs. Markt: ETON übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19.5 erzielte.
Preisvolatilität
| ETON volatility | |
|---|---|
| ETON Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: ETON hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ETONDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2017 | 44 | Sean Brynjelsen | www.etonpharma.com |
Eton Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von Therapien für seltene Krankheiten konzentriert. Zu den kommerziellen Produkten für seltene Krankheiten gehören Increlex zur Behandlung von schwerem primärem Igf-1-Mangel, Alkindi Sprinkle zur Behandlung von Nebenniereninsuffizienz, Khindivi zur Behandlung von Nebennierenrindeninsuffizienz, Galzin zur Behandlung der Wilson-Krankheit, PKU Golike zur Behandlung von Phenylketonurie, Carglumic Acid zur Behandlung von N-Acetylglutamat-Synthase-Mangel, Betaine Anhydrous zur Behandlung von Homocystinurie und Nitisinone zur Behandlung von Tyrosinämie Typ 1. Das Unternehmen entwickelt außerdem verschiedene Produktkandidaten, die sich in der Spätphase der Entwicklung befinden, darunter ET-600 für Diabetes insipidus, Amglidia für neonatalen Diabetes mellitus, ET-700 für Morbus Wilson, ET-800 für Nebenniereninsuffizienz und ZENEO Hydrocortison-Autoinjektor für Nebennierenkrisen.
Eton Pharmaceuticals, Inc.'s Grundlagenzusammenfassung
| ETON grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.02b |
| Gewinn(TTM) | -US$1.47m |
| Umsatz(TTM) | US$86.93m |
11.5x
Kurs-Umsatz-Verhältnis-679.9x
Kurs-Gewinn-Verhältnis Ist ETON zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ETON Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$86.93m |
| Kosten der Einnahmen | US$35.02m |
| Bruttogewinn | US$51.92m |
| Sonstige Ausgaben | US$53.39m |
| Gewinn | -US$1.47m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.054 |
| Bruttomarge | 59.72% |
| Nettogewinnspanne | -1.70% |
| Schulden/Eigenkapital-Verhältnis | 100.4% |
Wie hat sich ETON auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/10 02:57 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Eton Pharmaceuticals, Inc. wird von 5 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |